InvestorsHub Logo
Followers 829
Posts 119686
Boards Moderated 16
Alias Born 09/05/2002

Re: DewDiligence post# 1756

Tuesday, 05/07/2019 4:25:38 PM

Tuesday, May 07, 2019 4:25:38 PM

Post# of 2979
ENTA FY2Q19 results:

https://www.enanta.com/investors/news-releases/press-release/2019/Enanta-Pharmaceuticals-Reports-Financial-Results-for-its-Fiscal-Second-Quarter-Ended-March-31-2019/default.aspx

FY2Q19 royalty revenue was $39.6M, down from $69.9M in FY1Q19 (Oct-Dec 2018). ENTA’s royalty rate from ABBV resets to the lowest tier at the start of each calendar year, so ENTA’s fiscal 2Q (Jan-Mar) will always have the lowest royalty tier for a given fiscal year.

(The royalty tiers applicable to the 50% Glecaprevir component of Mavyret are shown in #msg-142808661.)

ENTA’s cash balance at 3/31/19 was $387M.

FY2Q19 GAAP EPS was $0.20, due to a tax benefit.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News